Skip to Main content Skip to Navigation
Journal articles

New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation

Abstract : Proviral integration site for Moloney murine leukemia virus (Pim)-1/2 kinase overexpression has been identified in a variety of hematologic (e.g., multiple myeloma or acute myeloid leukemia (AML)) and solid (e.g., colorectal carcinoma) tumors, playing a key role in cancer progression, metastasis, and drug resistance, and is linked to poor prognosis. These kinases are thus considered interesting targets in oncology. We report herein the design, synthesis, structure–activity relationships (SAR) and in vitro evaluations of new quinoxaline derivatives, acting as dual Pim1/2 inhibitors. Two lead compounds (5c and 5e) were then identified, as potent submicromolar Pim-1 and Pim-2 inhibitors. These molecules were also able to inhibit the growth of the two human cell lines, MV4-11 (AML) and HCT-116 (colorectal carcinoma), expressing high endogenous levels of Pim-1/2 kinases.
Complete list of metadata

https://www.hal.inserm.fr/inserm-03272339
Contributor : William Raoul Connect in order to contact the contributor
Submitted on : Monday, June 28, 2021 - 11:49:57 AM
Last modification on : Wednesday, December 1, 2021 - 2:36:52 PM
Long-term archiving on: : Wednesday, September 29, 2021 - 7:01:56 PM

File

molecules-26-00867-v2-1.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Bruno Oyallon, Marie Brachet-Botineau, Cédric Logé, Thomas Robert, Stéphane Bach, et al.. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation. Molecules, MDPI, 2021, 26 (4), pp.867. ⟨10.3390/molecules26040867⟩. ⟨inserm-03272339⟩

Share

Metrics

Record views

83

Files downloads

150